Mirum Pharmaceuticals (MIRM) announced that the FDA has approved Ctexli tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis. Ctexli is the first and only treatment approved for this rare, progressive and debilitating disease.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- MIRM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- FDA approves Mirum treatment for cerebrotendinous xanthomatosis
- Metagenomi appoints Eric Bjerkholt to board of directors
- Mirum Pharmaceuticals sees FY24 revenue $336M, consensus $332.78M
- Mirum Pharmaceuticals sees FY25 revenue $420M-$435M, consensus $418.15M